Foundation Medicine, Inc. announced that it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic for ALUNBRIG®, which is currently FDA-approved for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
[Foundation Medicine, Inc.]
7753456
{7753456:nan}
apa
50
1
164299
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/